Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …

HIV employs multiple means to evade the humoral immune response, particularly the
elicitation of and recognition by broadly neutralizing antibodies (bnAbs). Such antibodies …

The development of a protective vaccine remains a top priority for the control of the HIV/AIDS
pandemic. Here, we show that a messenger RNA (mRNA) vaccine co-expressing …

Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …

Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of
HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART …

Antibody responses to the HIV-1 envelope glycoproteins can be classified into three groups.
Binding but non-neutralizing responses are directed to epitopes that are expressed on …

A major goal of HIV-1 vaccine research is the design of immunogens capable of inducing
broadly neutralizing antibodies (bnAbs) that bind to the viral envelope glycoprotein (Env) …

Broadly neutralizing antibodies against highly variable viral pathogens are much sought
after to treat or protect against global circulating viruses. Here we probed the neutralizing …

Despite the success of potent anti-retroviral drugs in controlling human immunodeficiency
virus type 1 (HIV-1) infection, little progress has been made in generating an effective HIV-1 …

Broadly neutralizing HIV antibodies (bNAbs) can recognize carbohydrate-dependent
epitopes on gp120. In contrast to previously characterized glycan-dependent bNAbs that …